LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:LTRN

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/10	05 : 05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/10	05 : 02	Business Wire	Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/06	16 : 00	Business Wire	Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism	NASDAQ:LTRN	Lantern Pharma Inc
2024/05/02	20 : 30	Business Wire	Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET	NASDAQ:LTRN	Lantern Pharma Inc
2024/04/24	21 : 00	Business Wire	Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development	NASDAQ:LTRN	Lantern Pharma Inc
2024/04/22	21 : 12	Business Wire	Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/19	05 : 02	Business Wire	Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/18	20 : 12	IH Market News	Anticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See Upticks	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/15	21 : 00	Business Wire	Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/11	20 : 30	Business Wire	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/05	22 : 01	Business Wire	Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/04	22 : 01	Business Wire	Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines	NASDAQ:LTRN	Lantern Pharma Inc
2024/03/01	11 : 54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2024/02/15	22 : 01	Business Wire	Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers	NASDAQ:LTRN	Lantern Pharma Inc
2024/01/20	06 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2024/01/17	21 : 30	Business Wire	Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer	NASDAQ:LTRN	Lantern Pharma Inc
2023/12/30	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LTRN	Lantern Pharma Inc
2023/12/01	20 : 02	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:LTRN	Lantern Pharma Inc
2023/12/01	20 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LTRN	Lantern Pharma Inc
2023/11/30	22 : 00	Business Wire	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)	NASDAQ:LTRN	Lantern Pharma Inc
2023/11/25	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LTRN	Lantern Pharma Inc
2023/11/09	06 : 05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LTRN	Lantern Pharma Inc
2023/11/09	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LTRN	Lantern Pharma Inc
2023/11/09	06 : 01	Business Wire	Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights	NASDAQ:LTRN	Lantern Pharma Inc
2023/11/01	21 : 00	Business Wire	Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET	NASDAQ:LTRN	Lantern Pharma Inc
2023/10/21	06 : 25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LTRN	Lantern Pharma Inc
2023/10/10	21 : 00	Business Wire	Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET	NASDAQ:LTRN	Lantern Pharma Inc
2023/10/03	21 : 00	Business Wire	Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma	NASDAQ:LTRN	Lantern Pharma Inc
2023/09/25	21 : 30	Business Wire	Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors	NASDAQ:LTRN	Lantern Pharma Inc
2023/09/18	22 : 00	Business Wire	Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas	NASDAQ:LTRN	Lantern Pharma Inc